GLP-1 receptor agonists were found to be associated with a reduced incidence of atrial fibrillation in patients with cardiovascular risk factors.
Absolute Event Rate: 0% vs 0%
This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Basem M. Mishriky has served on Advisory Board Panel for AstraZeneca and the consulting fees from AstraZeneca paid to the East Carolina University. Doyle M. Cummings has received research grant support from Novo-Nordisk Pharmaceuticals. The other authors declare that there are no conflict of interests. The peer review history for this article is available at https://publons.com/publon/10.1002/DMRR.3436. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Hamedi et al. (Fri,) reported a other. GLP-1 receptor agonists were found to be associated with a reduced incidence of atrial fibrillation in patients with cardiovascular risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: